SCHEMBL4064776

SCHEMBL4064776

CCNC(C)Cc1ccc2c(c1)OC(CNC(=O)CCN1C(=O)C=CC1=O)O2

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
THRB P10828 1/20 0.38
TSHR P16473 1/20 0.35
CYP3A4 P08684 4/20 0.35
CYP2C19 P33261 3/20 0.35
CYP2C9 P11712 2/20 0.34
CYP1A2 P05177 1/20 0.34
CYP2D6 P10635 1/20 0.34
TP53 P04637 1/20 0.32
ALDH1A1 P00352 2/20 0.32
SLC6A4 P31645 3/20 0.32
SIGMAR1 Q99720 2/20 0.32
OPRK1 P41145 2/20 0.32
OPRM1 P35372 1/20 0.32
OPRD1 P41143 1/20 0.32
POLB P06746 1/20 0.31
HPGD P15428 1/20 0.31
TDP1 Q9NUW8 1/20 0.31
ADRA2C P18825 2/20 0.31
ADRA1A P35348 2/20 0.31
LMNA P02545 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14491627 0.82 THRB (0.35) THRBTSHRCYP3A4CYP2C19CYP2C9
SCHEMBL13749303 0.79 AKT1 (0.35) THRBTSHRCYP3A4CYP2C19CYP2C9
SCHEMBL4067265 0.73 SIGMAR1 (0.43) SIGMAR1LMNAMAPTL3MBTL1
SCHEMBL4064784 0.70 SIGMAR1 (0.35) TSHRCYP2C19CYP1A2CYP2D6TP53
SCHEMBL4062857 0.67 ACE (0.40)
SCHEMBL4070023 0.67
SCHEMBL2754833 0.67 PTGS1 (0.44) CYP2C19CYP1A2TP53ALDH1A1POLB
SCHEMBL6288260 0.64 TAAR1 (0.53) TSHRCYP3A4CYP2D6ALDH1A1SLC6A4
SCHEMBL13749079 0.64 HTT (0.33) THRBALDH1A1LMNAL3MBTL1
SCHEMBL12201716 0.63 KAT2A (0.39) CYP2C19CYP1A2TP53ALDH1A1OPRK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569676-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2009-08-04 US disclosed
EP-1498415-B1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS GMBH (DE) 2007-06-27 EP disclosed
US-7060847-B2 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS OPERATIONS, INC. (US) 2006-06-13 US disclosed
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs GHOSHAL MITALI (US) 2005-07-14 US disclosed
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs ROCHE DIAGNOSTICS CORPORATION 2005-01-20 US disclosed
EP-1498415-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs Roche Diagnostics GmbH (DE) 2005-01-19 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050014210-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 THRB 4540/4885TSHR 4264/4885CYP3A4 796/4885
US-20050153439-A1 Ecstasy-class derivatives, immunogens, and antibodies and their use in detecting ecstasy-class drugs DRD3, SLC6A3, DRD2 THRB 4540/4885TSHR 4264/4885CYP3A4 796/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.